In this review, we focus on the involvement of MSX2 in the enhancement of malignant behavior in PDAC and IPMN, and further highlight the clinical approach to differentiate PDAC from chronic pancreatitis by evaluating MSX2 expression level. This evidence concerns the gene MSX2 and pancreatic intraductal papillary-mucinous neoplasm.